[go: up one dir, main page]

WO2024263638A3 - Composition pharmaceutique et utilisations de celle-ci - Google Patents

Composition pharmaceutique et utilisations de celle-ci Download PDF

Info

Publication number
WO2024263638A3
WO2024263638A3 PCT/US2024/034614 US2024034614W WO2024263638A3 WO 2024263638 A3 WO2024263638 A3 WO 2024263638A3 US 2024034614 W US2024034614 W US 2024034614W WO 2024263638 A3 WO2024263638 A3 WO 2024263638A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
characterizing
treating
detecting
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/034614
Other languages
English (en)
Other versions
WO2024263638A2 (fr
Inventor
I-Fan Wang
Hsiang-Yu Chang
Chen-Hung Ting
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeefan Med Inc
Original Assignee
Yeefan Med Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeefan Med Inc filed Critical Yeefan Med Inc
Publication of WO2024263638A2 publication Critical patent/WO2024263638A2/fr
Publication of WO2024263638A3 publication Critical patent/WO2024263638A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sont présentement décrites des compositions pharmaceutiques et des méthodes de traitement, de détection, de caractérisation et de réduction de protéines de mauvais repliement et de prévention de maladies associées telles que des maladies neurodégénératives et un vieillissement normal.
PCT/US2024/034614 2023-06-20 2024-06-19 Composition pharmaceutique et utilisations de celle-ci Pending WO2024263638A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363521954P 2023-06-20 2023-06-20
US63/521,954 2023-06-20

Publications (2)

Publication Number Publication Date
WO2024263638A2 WO2024263638A2 (fr) 2024-12-26
WO2024263638A3 true WO2024263638A3 (fr) 2025-04-17

Family

ID=93936209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034614 Pending WO2024263638A2 (fr) 2023-06-20 2024-06-19 Composition pharmaceutique et utilisations de celle-ci

Country Status (1)

Country Link
WO (1) WO2024263638A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
US8263589B2 (en) * 2006-03-29 2012-09-11 Wista Laboratories Ltd. Inhibitors of protein aggregation
US20160206609A1 (en) * 2011-08-12 2016-07-21 Salk Institute For Biological Studies Neuroprotective polyphenol analogs
WO2023019351A1 (fr) * 2021-08-16 2023-02-23 University Health Network Méthodes et compositions pour le traitement de la neurodégénérescence induite par l'alpha-synucléine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263589B2 (en) * 2006-03-29 2012-09-11 Wista Laboratories Ltd. Inhibitors of protein aggregation
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
US20160206609A1 (en) * 2011-08-12 2016-07-21 Salk Institute For Biological Studies Neuroprotective polyphenol analogs
WO2023019351A1 (fr) * 2021-08-16 2023-02-23 University Health Network Méthodes et compositions pour le traitement de la neurodégénérescence induite par l'alpha-synucléine

Also Published As

Publication number Publication date
WO2024263638A2 (fr) 2024-12-26

Similar Documents

Publication Publication Date Title
Guha et al. Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1
Li et al. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression
WO2020123300A3 (fr) Molécules d'arnm variant de kras
NZ778565A (en) Compositions containing, methods and uses of antibody-tlr agonist conjugates
NO20053114L (no) Astma og allergisk inflammasjonsmodulatorer.
EP4516800A3 (fr) Compositions de protéines anti-vegf et procédés de production associés
WO2004101606A3 (fr) Nouveaux peptides se fixant au recepteur de l'erythropoietine
WO2004009062A3 (fr) Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
WO2021107656A3 (fr) Nouveau dérivé d'oxydo-réduction de la quercétine et son utilisation en tant qu'inhibiteur de bet
WO2019032936A8 (fr) Antibiotiques linconsamides et leurs utilisations
EP4289480A3 (fr) Antibiotiques macrocycliques à large spectre
WO2008079270A3 (fr) Coadministration d'alpha-foetoprotéine et d'un agent immunomodulateur pour traiter la sclérose en plaques
EP4480538A3 (fr) Formes solides de mavacamten et leur procédé de préparation
WO2007008069A3 (fr) Methode de detection et/ou d'extraction d'une proteine a structure 'cross-beta' dans une composition pharmaceutique
MX2025003937A (es) Formas cristalinas de un agente anti-sars cov-2
WO2022169755A8 (fr) N-(1h-indol-7-yl)benzènesulfonamides à substitution sulfonamide et leurs utilisations
WO2024263638A3 (fr) Composition pharmaceutique et utilisations de celle-ci
WO2024030856A3 (fr) Protéines immunomodulatrices et méthodes associées
EP3964520A4 (fr) Nouvel oligopeptide et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif
WO2025083472A3 (fr) Composés protac se liant à l'ubiquitine ligase keap1 pour la dégradation ciblée de protéines
EP4241776A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la fibrose, comprenant des mitochondries isolées
WO2020154420A3 (fr) Dérivés d'acides aminés pour le traitement de maladies inflammatoires
WO2021024209A9 (fr) Anticorps qui se lient à des espèces tau pathologiques et leurs utilisations
WO2024163530A3 (fr) Nouveaux anticorps anti-ccr4 et produits dérivés
WO2024035899A3 (fr) Molécules d'acide polynucléique ciblant apoc3 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24826569

Country of ref document: EP

Kind code of ref document: A2